Current Trends and Challenges in the Excipients Market - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Current Trends and Challenges in the Excipients Market


Pharmaceutical Technology


Excipients can enable enhanced drug effectiveness in important ways. They already are used to control the drug's absorption into the body. Disintegrants, for example, allow the tablet to break up into particles that are small enough to enter blood vessels. Excipients can perform many other functions such as improving the safety, stability, and storage of medicines. So, it is no surprise that excipients are becoming a more important aspect in tablet manufacture than they were previously and are even helping innovate drug formulations.

Present and future markets

Excipient production is overwhelmingly based in North America and Europe. These two regions currently account for more than 75% of the market, according to a Frost and Sullivan study (3). Demand is likely to increase as further innovations take hold and excipients are adapted for more uses.

While the European and North American markets are anticipated to continue growing during the next five years, both China and India will be in a position to enter the market during this time. The ability of both countries to combine low-cost manufacturing capability without compromising on quality will certainly have a significant effect on the established markets.

Conclusion

Excipients historically have been overlooked by many in the pharmaceutical industry in favor of active ingredients. In the light of the challenges from generics producers, falling revenues, and the decline of the blockbuster drugs as big revenue generators, however, excipients offer many opportunities to meet some of these challenges. In particular, excipients can be used to cut drug-development costs without adversely affecting the quality of the products.

The line between active ingredients and excipients has therefore become more blurred as the latter increasingly are coming to be seen as functional materials rather than inactive bulking agents. New developments such as the use of natural starch-based products, biotechnological research, and the use of nanotechnology to manipulate small molecules all mean that the range and uses for excipients are likely to increase. Examples in recent years include using mannitol in oral-dispersal tablets and speciality starch grades for slow-release applications.

Excipients' functional characteristics and increasing attractiveness to Big Pharma for cost-reduction reasons make it likely that market conditions for excipients will remain promising for the next few years.

James Taylor is category leader at Cargill Pharma and Personal Care, Bedrijvenlaan, 9, 2800 Mechelen, Belgium, tel. 132 0 15 400 508, fax 132 0 15 400 591,

References

1. "Combating Generics: Pharmaceutical Brand Defense," Cutting Edge Information (Research Triangle Park, NC, 2006) http://www.cuttingedgeinfo.com/pharmagenerics, accessed Sept. 7, 2006.

2. "IPEC Europe News," International Pharmaceutical Excipients Council-Europe (Nov. 2005), http://www.ipec-europe.org/docs/pdf/newsletters, accessed Sept. 7, 2006.

3. "Strategic Analysis of Pharmaceutical Excipients Market in Europe," Frost & Sullivan (San Antonio, TX, May 12, 2005) http://www.frost.com/prod/servlet/frost-home. pag, accessed Sept. 7, 2006.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here